Based on the above discovery, the mTOR inhibitor everolimus was chosen to interfere with METTL3/miR-17-92 cluster/TMEM127 or PTEN/mTOR signaling pathway in gastric cancer. This evidence concerns the gene TMEM127 and gastric cancer.